Hodnota metriky P/FCF spoločnosti InVivo Therapeutics Holdings Corp je N/A
Price to free cash flow (P/FCF) je metóda hodnotenia spoločnosti, ktorá dáva do pomeru aktuálnu cenu akcie spoločnosti a peňažný tok na jednu akciu.
Price to free cash flow (P/FCF) is a measure that value investors find useful to analyze a company’s finances in relation to its current stock price. It is a stricter measure than the price to cash flow ratio as it subtracts capital expenditures from cash flow.
Free cash flow relies heavily on the state of a company's cash from operations, which is in turn heavily influenced by the company's net income. Companies can manipulate their free cash flow by lengthening the time they take to pay their bills, shortening the time it takes to collect what's owed to them, and putting off buying inventory. It also depends on what items are considered capital expenditures and this can be different in case of different companies.
Lower values of P/FCF generally indicate a company that is undervalued and whose stock is relatively cheap in relation to its free cash flow. Conversely, higher P/FCF indicate that the company's stock is relatively overvalued. Value investors thus favor companies with low or decreasing price to free cash flow values that indicate high or increasing free cash flow totals and relatively low stock share prices.
It is best to compare price to free cash flow ratios between similar companies in the same industry. However, the P/FCF metric can also be viewed over a longer time frame to see if the company's cash flow to share price value is improving or declining.
about invivo therapeutics invivo therapeutics holdings corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. the company was founded in 2005 with proprietary technology co-invented by robert langer, sc.d., professor at massachusetts institute of technology, and joseph p. vacanti, m.d., who then was at boston children’s hospital and who now is affiliated with massachusetts general hospital. in 2011, the company earned the david s. apple award from the american spinal injury association for its outstanding contribution to spinal cord injury medicine. in 2015, the company’s investigational neuro-spinal scaffold received the 2015 becker’s healthcare spine device award. the publicly-traded company is headquartered in cambridge, ma. for more details, visit www.invivotherapeutics.com. about the neuro-spinal scaffold™ following acute spinal cord injury, surgical implantation of the biodegradable neuro-spinal scaffold wi